Although the current study was not designed to test treatment effects, these chromosomal structural and sequence-level alterations; used as surrogates for underlying genomic instability or apoptotic resistance, may help identify CLL subsets most likely to benefit from next-generation BCR pathway inhibitors, BCL2 antagonists, or cellular therapies. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.